Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
7.42
-0.20 (-2.62%)
At close: May 30, 2025, 4:00 PM
7.05
-0.37 (-4.99%)
After-hours: May 30, 2025, 6:02 PM EDT
CRBP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
90.80M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CRBP News
- 9 days ago - Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 12 days ago - Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewsWire
- 2 months ago - Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity - GlobeNewsWire
- 3 months ago - CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 5 months ago - Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors - GlobeNewsWire